Skip to main content

Grafa News and Videos — Page 521

Grafa Headlines

Grafa

Vertex receives FDA approval for expanded CASGEVY use in children

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced that the U.S. Food and Drug Administration has approved expanded use of CASGEVY (exagamglogene autotemcel) for the treatment of people ages 2 years and older with either sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.

Read more: Vertex receives FDA approval for expanded CASGEVY use in children

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift